| Ident. | Authors (with country if any) | Title |
|---|
| 000093 (2020) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Some concerns from Turkey' by Bilgin et al. |
| 000094 (2020) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. |
| 000124 (2020) |
Yoshikazu Nakaoka ; Mitsuaki Isobe ; Yoshiya Tanaka ; Tomonori Ishii ; Seido Ooka ; Hiroaki Niiro [Japon] ; Naoto Tamura ; Shogo Banno ; Hajime Yoshifuji [Japon] ; Yasushi Sakata ; Atsushi Kawakami ; Tatsuya Atsumi ; Shunsuke Furuta ; Hitoshi Kohsaka ; Katsuya Suzuki ; Ryoki Hara ; Yasuhiro Maejima ; Hiroshi Tsukamoto ; Yoshinari Takasaki ; Katsuhisa Yamashita ; Norihiro Okada ; Shinji Yamakido ; Syuji Takei ; Shumpei Yokota [Japon] ; Norihiro Nishimoto [Japon] | Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. |
| 000207 (2020) |
Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Aya Nawata [Japon] ; Kentaro Hanami [Japon] ; Satoshi Kubo [Japon] ; Ippei Miyagawa [Japon] ; Yoshihisa Fujino [Japon] ; Shingo Nakayamada [Japon] ; Yoshiya Tanaka [Japon] | Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. |
| 000362 (2019) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. |
| 000386 (2019) |
Masaru Kato [Japon] ; Yuko Kaneko [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Isao Yokota [Japon] ; Tatsuya Atsumi [Japon] ; Tsutomu Takeuchi [Japon] | Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. |
| 000424 (2019) |
Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] ; Reiji Yamakawa [Japon] | Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. |
| 000640 (2018) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonoti Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. |
| 000652 (2018) |
Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). |
| 000844 (2018) |
Yoshikazu Nakaoka [Japon] ; Mitsuaki Isobe [Japon] ; Syuji Takei [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Shumpei Yokota [Japon] ; Akira Nomura [Japon] ; Seitaro Yoshida [Japon] ; Norihiro Nishimoto [Japon] | Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). |
| 000852 (2018) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. |
| 000868 (2018) |
Shingo Nakayamada [Japon] ; Satoshi Kubo [Japon] ; Maiko Yoshikawa [Japon] ; Yusuke Miyazaki [Japon] ; Naoki Yunoue [Japon] ; Shigeru Iwata [Japon] ; Ippei Miyagawa [Japon] ; Shintaro Hirata [Japon] ; Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. |
| 000930 (2018) |
Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] | A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. |
| 000B71 (2017) |
Naoki Ishiguro [Japon] ; Tatsuya Atsumi [Japon] ; Masayoshi Harigai [Japon] ; Tsuneyo Mimori [Japon] ; Norihiro Nishimoto [Japon] ; Takayuki Sumida [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Ayako Nakasone [Japon] ; Nobuhiro Takagi ; Hisashi Yamanaka [Japon] | Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. |
| 000E93 (2016) |
Satoshi Kubo [Japon] ; Shingo Nakayamada [Japon] ; Kazuhisa Nakano [Japon] ; Shintaro Hirata [Japon] ; Shunsuke Fukuyo [Japon] ; Ippei Miyagawa [Japon] ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. |
| 000E96 (2016) |
Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). |
| 001025 (2015) |
Shintaro Hirata [Japon] ; Anthony Marotta [Canada] ; Yuan Gui [Canada] ; Kentaro Hanami [Japon] ; Yoshiya Tanaka [Japon] | Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. |
| 001073 (2015) |
Atsushi Ogata ; Koichi Amano ; Hiroaki Dobashi ; Masayuki Inoo ; Tomonori Ishii ; Tsuyoshi Kasama ; Shinichi Kawai ; Atsushi Kawakami ; Tatsuya Koike ; Hisaaki Miyahara ; Toshiaki Miyamoto ; Yasuhiko Munakata ; Akira Murasawa ; Norihiro Nishimoto ; Noriyoshi Ogawa ; Tomohiro Ojima ; Hajime Sano ; Kenrin Shi ; Eisuke Shono ; Eiichi Suematsu ; Hiroki Takahashi ; Yoshiya Tanaka ; Hiroshi Tsukamoto ; Akira Nomura | Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. |
| 001111 (2015) |
Ryoko Sakai [Japon] ; Soo-Kyung Cho [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Michi Tanaka [Japon] ; Ryuji Koike [Japon] ; Yoshiya Tanaka [Japon] ; Kazuyoshi Saito [Japon] ; Shintaro Hirata [Japon] ; Koichi Amano [Japon] ; Hayato Nagasawa [Japon] ; Takayuki Sumida [Japon] ; Taichi Hayashi [Japon] ; Takahiko Sugihara [Japon] ; Hiroaki Dobashi [Japon] ; Shinsuke Yasuda [Japon] ; Tetsuji Sawada [Japon] ; Kazuhiko Ezawa [Japon] ; Atsuhisa Ueda [Japon] ; Takao Fujii [Japon] ; Kiyoshi Migita [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon] | Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. |
| 001283 (2014) |
Ippei Miyagawa [Japon] ; Shingo Nakayamada ; Kazuyoshi Saito ; Kentaro Hanami ; Masao Nawata ; Norifumi Sawamukai ; Kazuhisa Nakano ; Kunihiro Yamaoka ; Yoshiya Tanaka | Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. |
| 001373 (2014) |
Takao Koike [Japon] ; Masayoshi Harigai ; Shigeko Inokuma ; Naoki Ishiguro ; Junnosuke Ryu ; Tsutomu Takeuchi ; Syuji Takei ; Yoshiya Tanaka ; Yoko Sano ; Hitomi Yaguramaki ; Hisashi Yamanaka | Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. |
